LAVA Medtech Acquisition Corp. (the “Company”) today announced the closing of its initial public offering of 11,500,000 units at a price of $10.00 per unit, including 1,500,000 units pursuant to the full exercise of the underwriters’ over-allotment option. The offering was …
Trending at Lumira Ventures
GenEp Raises $1.45 Million Seed Financing
GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira …
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML). This investigator-initiated trial is being led …
HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy
HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of …
Invest in BC Presented by Lumira Ventures: Life Sciences BC Announces Presenting Companies Pitching
VANCOUVER, British Columbia – Life Sciences British Columbia (LSBC) announces the 31 companies presenting to the 6th annual Invest in BC presented by Lumira Ventures on November 3 and 4, 2021. This virtual conference showcases a broad range of investor-ready …
OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure
QUEBEC, Quebec, October 13, 2021 – OpSens Inc. (TSX:OPS), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire, and successful …
The Industry of Biotechnology is on the rise and Canadian LPs are waking up: Peter van der Velden and Anthony Mouchantaf (RBCx) discuss why on Tank Talks by Ripple Ventures
Over the years we have seen a surge in investor interest and deal making in biotech. Lumira Ventures General Partner and Managing Director, Peter van der Velden is joined by Anthony Mouchantaf, Director, Venture Capital at RBCx and Tank Talks …